KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EPS (Weighted Average and Diluted) (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with $6.75 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) fell 7.15% year-over-year to $6.75; the TTM value through Mar 2026 reached $41.05, up 4.37%, while the annual FY2025 figure was $41.48, 8.19% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $6.75 in Q1 2026 for Regeneron Pharmaceuticals, down from $7.87 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $13.62 in Q3 2025 and bottomed at $6.27 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is $9.39, with a median of $8.61 recorded in 2022.
  • Year-over-year, EPS (Weighted Average and Diluted) tumbled 73.29% in 2022 and then surged 46.0% in 2024.
  • Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $10.49 in 2022, then fell by 2.76% to $10.2 in 2023, then dropped by 20.49% to $8.11 in 2024, then fell by 2.96% to $7.87 in 2025, then dropped by 14.23% to $6.75 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $6.75, $7.87, and $13.62 for Q1 2026, Q4 2025, and Q3 2025 respectively.